Oct 1, 2024 | Genomics, Kurt Harden, News, Nutrigenomics, Pharmacies, Pharmacogenomics, Wellness
MedBen Chairman & CEO Kurt Harden and Profero Team Director of Precision Medicine Cynthia Yu were featured presenters at the 11th Annual Sherrill-Morgan Healthcare Innovation Conference on September 18th. Harden and Yu spoke on the topic of genomic testing — what...
Sep 3, 2024 | Biosimilar, Drug costs, GLP-1s, Humira, Mounjaro, Ozempic, Rx Costs, Stelara, Trulicity, Wegovy
Humira continued to be the costliest prescription drug for self-funded health plans in 2023 by a comfortable margin, according to a recent Milliman commercial drug trends review. Used to treat a variety of conditions from Crohn’s to rheumatoid arthritis and psoriatic...
Aug 15, 2024 | Food and Drug Administration (FDA), MDMA (ecstasy), Psychedelic drugs
The potential for psychedelic drugs to serve legitimate medical purposes has become a growing topic of discussion. On August 9, the Food and Drug Administration rejected midomafetamine (MDMA), better known as ecstasy, as a treatment for post-traumatic stress disorder....
Aug 5, 2024 | Biosimilar, Cost Savings, Food and Drug Administration (FDA), Humalog, Opinions, Savings
From a STAT opinion piece by Juliana M. Reed, executive director of the Biosimilars Forum: “Biologic medicines are some of the most important drugs in the world. They are also among the most expensive. Biosimilars are FDA-approved treatments that are similar to...
Jul 23, 2024 | Federal Trade Commission (FTC), Formularies, News, Pharmacy Benefits Manager (PBM)
In an interim report released on July 9, the Federal Trade Commission charges major pharmacy benefit managers of engaging in business practices designed to benefit their own bottom lines at the expense of clients. The FTC report, subtitled “The Powerful...